Citations

Clear

2960 citation(s) found for "Kim, P".

Functional Improvement in Cranial Neuropathies From Perineural Cutaneous Squamous Cell Carcinoma After Immunotherapy: A Multicenter Case Series and Review
Saffari, Persiana S. , Lucarelli, Katherine M., Tooley, Andrea A. , Goldberg, Robert A., Rootman, Daniel B. , Badilla, Jaime, Liu, Daisy , Kim, Irene A., Demirci, H., Juntipwong, Sarinee , Roelofs, Kelsey A. , Homer, Natalie Anne , Wolkow, Natalie , Demirci, Hakan

Mayo Clinic

Ophthalmic Plastic & Reconstructive Surgery | January 13, 2026 | Volume: 42 | Issue: 2 | Pages: 207-212

10.1097/iop.0000000000003057 | PMID 41528941 Get It

Purpose: Cutaneous squamous cell carcinoma has a propensity for perineural invasion. Treating perineural spread has involved surgery and adjuvant chemoradiation, and more recently, immune checkpoint inhibitors. This study aims to evaluate motor and sensory functional outcomes in patients with cranial neuropathies from perineural spread of squamous cell carcinoma, particularly those undergoing immunotherapy. Methods: This was a multicenter case series and literature review. Results: Eighteen patients with cranial neuropathies from perineural spread had a mean age of 72.5 ± 9.7 years. Cranial nerves V and VII were most often involved. Treatments included radiotherapy (8/18; 44.4%), chemotherapy (7/18; 38.9%), and/or immunotherapy (11/18; 61.1%), with many receiving a combination of modalities (8/18; 44.4%). Of those receiving immunotherapy, 72.7% (8/11) demonstrated at least partial clinical and/or radiologic tumor response. Among those with functional outcomes documented, half had improvement in sensory/motor nerve function following immunotherapy (4/8; 50%). A literature review identified 55 articles describing 449 patients total with cranial neuropathies from squamous cell carcinoma perineural spread. Combinations of surgery, chemotherapy, and/or radiotherapy were employed, with immunotherapy used in 16 patients. From 5 patients on immunotherapy with documented functional outcomes, all demonstrated at least some improvement. Conclusion: Immunotherapy plays an evolving role in managing advanced squamous cell carcinoma. Functional improvements in cranial neuropathy were demonstrated in 50% of patients receiving treatment with immunotherapy at a mean of 32.6 months of follow-up. This may hold important implications for the timing of surgical intervention, particularly in the case of cranial nerves V and VII palsies.
Efficacy and safety of lirafugratinib in FGFRi -naïve cholangiocarcinoma (CCA) patients harboring FGFR2 fusions/rearrangements ( FGFR2
Lu, Peter, Meng, Xianzhang, Ryan, Kristin, Alexander, Laura M., Liu, Jia, Oh, Do-Youn, Hollebecque, Antoine , Borad, Mitesh J. , Meng, Xianzhang, Alexander, Laura, Oh, Do‐Youn , Kim, Richard D.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 476-476

10.1200/jco.2026.44.2_suppl.476 Get It

476 Background: Outcomes remain poor for patients with advanced/metastatic CCA treated with first-line gemcitabine-cisplatin +/- anti-PD(L)1. Lirafugratinib is the first highly selective, irreversible FGFR2 inhibitor designed to target oncogenic FGFR2 driver alterations and resistance mutations. ReFocus (NCT04526106) is an open-label, multicenter phase 1/2 study in patients with advanced/metastatic CCA and other solid tumors with FGFRok2 alterations. Methods: Pivotal cohort of patients (n=116) with advanced/metastatic CCA harboring FGFR2 f/r previously treated with ≥1 systemic therapy and FGFR i-naive were treated with oral lirafugratinib 70 mg once daily until disease progression or unacceptable toxicity. The primary endpoint was confirmed ORR per RECIST v1.1 by independent review committee (IRC). Key secondary endpoint was duration of response (DOR); other secondary endpoints: disease control rate (DCR), progression-free survival (PFS), overall survival (OS), safety, and quality of life per EORTC QLC-C30. Results: As of 27SEP2024, the primary efficacy analysis of IRC-assessed data (n=114) and the secondary analysis of investigator-assessed data (n=116) set was done. The primary efficacy analysis excluded 2 patients as not available. Median age 57 years with 61.4% female. IRC-assessed ORR was 47%, and median DOR was 11.8 months (mos) (95% CI, 7.5-13.0), where 76.2% of responses lasted >6 mos. Median PFS was 11.3 mos (95% CI, 9.2, 14.8), with 12-month rate of 49.2%. Median OS was 22.8 mos (95% CI, 17.3-27.2), with 12-month rate of 74.6%. DCR was 96.5%. Common grade ≥3 on-target, off-tumor treatment-related adverse events (TRAEs) included palmar-plantar erythrodysesthesia (32.8%) and stomatitis (12.1%). TRAEs led to dose reductions of 75.9%, dose interruption of 82.8%, and treatment discontinuation of 4.3%. QoL was maintained. Conclusions: Lirafugratinib demonstrated clinically meaningful anti-tumor activity (ORR, DOR, and PFS), manageable and tolerable safety in CCA FGFR2 f/r patients. Clinical trial information: NCT04526106 . Best Overall Response, n (%) IRC c Investigator d Complete Response Partial Response Stable Disease Progression Disease Not Evaluable 3 (2.6)50 (43.9)57 (50.0)3 (2.6)1 (0.9) 061 (52.6)51 (44.0)3 (2.6)1 (0.9) ORR a , n (%)95% CI 53 (46.5)37.1, 56.1 61 (52.6)43.1, 61.9 DCR b , n (%)95% CI 110 (96.5)91.3, 99.0 112 (96.6)91.4, 99.1 a ORR defined as proportion achieving confirmed response of complete response or partial response per RECIST v1.1. b DCR defined as proportion with confirmed response of complete response, partial response, or stable disease per RECIST v1.1. c Primary Efficacy Analysis Set. d Secondary Efficacy Analysis Set. Percentages based on number of patients in the analysis set for each treatment arm. Exact Clopper-Pearson used for 95% CI. IRC and investigator assessments are based on different populations and cannot compare directly.
Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT as first-line treatment for locally advanced (LA), unresectable esophageal squamous cell carcinoma (ESCC): PD-L1 tumor area positivity (TAP) score ≥1% subgroup analysis of RATIONALE-306.
Yoon, Harry H. , Kim, S., Xu, J., Kato, Ken, Wei, Bo, Yan, Simin , Kong, Xuan, AJANI, J. A., Kato, Ken, Ajani, Jaffer A.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 381-381

10.1200/jco.2026.44.2_suppl.381 Get It

381 Background: In RATIONALE-306 (NCT03783442), patients (pts) with LA unresectable or metastatic ESCC who received TIS (intravenously, 200 mg, every 3 weeks) + CT (platinum + fluoropyrimidine or paclitaxel) had longer median overall survival (OS) than pts who received PBO + CT at the interim analysis; improvement was maintained after a ≥3-year follow-up. Post hoc analyses in the PD-L1 TAP ≥1% subgroup showed clinically meaningful improvement with TIS + CT. These data supported the US FDA approval for unresectable or metastatic ESCC. Here we report the subgroup analysis of pts who had LA ESCC with PD-L1 TAP score ≥1%. Methods: Pts who had LA unresectable ESCC with PD-L1 TAP score ≥1% were included in this post hoc analysis. Efficacy outcomes (OS, progression-free survival [PFS], objective response rate [ORR], duration of response [DoR]) and safety were analyzed. Results: At data cutoff (Feb 28, 2022), of 649 pts randomized, 63 had LA ESCC with PD-L1 TAP score ≥1% (TIS + CT n=31; PBO + CT n=32; median age 67.0 years; 85.7% male). At median follow-up (TIS + CT 24.4 months; PBO + CT 24.5 months), efficacy with TIS + CT was improved vs PBO + CT (Table) and was consistent with the intent-to-treat (ITT) population. Efficacy was maintained after a ≥3-year follow-up (data cutoff: Nov 24, 2023; Table). Conclusions: In this post-hoc analysis, the median OS for pts receiving TIS + CT exceeded two years. The regimen was well tolerated. While the findings require validation in future clinical trials, first-line TIS + CT is an encouraging option for pts who have LA unresectable ESCC with PD-L1 TAP score ≥1%. Clinical trial information: NCT03783442 . Interim Analysis 3-Year Follow-up TIS + CT (n=31) PBO + CT (n=32) TIS + CT (n=32) e PBO + CT (n=31) f Median OS, mo(95% CI) 25.6 (15.3, NE) 11.5(9.0, 21.8) 25.6 (15.3, NE) 12.3(9.0, 21.8) HR (95% CI) a 0.36 (0.17, 0.77) – 0.50 (0.26, 0.95) – Median PFS, a mo(95% CI) 13.2(6.8, NE) 6.7(4.2, 9.7) 13.2(6.8, 27.7) 6.7(4.2, 9.7) HR (95% CI) a 0.46 (0.22, 0.96) – 0.47 (0.23, 0.96) – ORR, b,c n (%) 18 (58.1) 10 (31.3) 19 (59.4) 10 (32.3) Median DoR, b,d mo(95% CI) Not reached (8.4, NE) 5.7 (1.5, 9.6) 22.1 (6.1, NE) 5.7 (1.5, 9.6) a Stratified. b Investigator assessed. c Unconfirmed. d Based on unconfirmed ORR. e One patient’s disease status at baseline was changed to LA after interim analysis. f One patient’s disease status at baseline was changed to metastatic after interim analysis. NE, not estimable.
Modeling analysis of RATIONALE-305: Impact of peritoneal metastasis (PM) representation on clinical outcomes in patients (pts) treated with tislelizumab plus chemotherapy (TIS+CT) with gastric cancer/gastroesophageal junction cancer (GC/GEJC).
Rha, Sun Young, Xu, Rui-Hua, Pietrantonio, Filippo, Moehler, Markus H., Kato, Ken, Alsina, María , Kim, H., Xu, Yaling, Kong, Xuan, Zhao, Na, Lorenzen, Sylvie, Sonbol, Mohamad Bassam , Rha, Sun Young , Xu, Rui‐Hua , Pietrantonio, Filippo , Kato, Ken, Zhao, Na

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 378-378

10.1200/jco.2026.44.2_suppl.378 Get It

378 Background: RATIONALE-305 (NCT03777657) enrolled the highest number of pts with PM among similar trials and stratified pts with advanced GC/GEJC by presence of PM. We used statistical modeling to evaluate the impact of varying PM levels on outcomes with TIS+CT. Methods: We randomized adults with GC/GEJC (1:1) to TIS or placebo (PBO) + CT. Primary endpoints: OS in intent-to-treat (ITT) population and pts with programmed death-ligand 1 (PD-L1) Tumor Area Positivity (TAP) score ≥5%. We weighted pts using the method of moments to match a hypothetical population to ITT, with the same distribution of sex, primary tumor location, PD-L1 (TAP score <5% vs ≥5%), number of metastatic sites (0-2 vs 3+), and liver metastasis. PM representation was set from 20% to 45%. Weighted OS, PFS, and objective response rate (ORR) were estimated. Results: Of 997 pts enrolled, 434 (43.5%) had PM. Among pts with PD-L1 TAP scores ≥5% (54.8%), 39.7% had PM, and among pts with scores ≥1% (88.9%), 43.6% had PM (data cutoff Feb 28, 2024). Fewer pts with (+) PM had PD-L1 high tumors (TAP score ≥5%: 50.0%) and more had primary stomach tumors (86.6%) compared to those without (-) PM (58.4% and 75.5%). TIS+CT improved OS, PFS, and ORR in ITT and in pts +/- PM vs PBO+CT (Table). Across 20%–45% PM, TIS+CT showed consistent benefit, with stable HRs for OS and PFS (20% and 45% shown). TIS+CT showed survival benefits in pts with PM and PD-L1 TAP score ≥5% (OS: HR=0.71; PFS: HR=0.65) and ≥1% (OS: HR=0.79; PFS: HR=0.79) vs PBO+CT. ORR was higher with TIS+CT vs PBO+CT in pts + PM and PD-L1 TAP scores ≥5% (47.3% vs 30.8%) and ≥1% (44.2% vs 33.2%). Conclusions: Our analysis showed that lowering PM representation marginally improved OS and ORR, underscoring the poor prognosis of peritoneal disease. In RATIONALE-305, TIS+CT provides clinically meaningful response and survival benefits irrespective of PM, with higher responses in PD-L1+ GC/GEJC. Clinical trial information: NCT03777657 . Arm(95% CI) ITT + PM - PM 20%+ PM 45%+ PM OS, months TIS+CT 15.0 (13.6, 16.5) 12.3 (10.6, 14.3) 17.3 (15.0, 20.3) 15.4 (13.9, 18.0) 15.0 (13.5, 16.5) PBO+CT 12.9 (12.1, 14.1) 11.8 (10.5, 13.0) 14.0 (12.6, 16.0) 13.1 (12.3, 14.5) 12.8 (12.1, 14.1) HR 0.79 (0.69, 0.91) 0.78 (0.64, 0.96) 0.79 (0.65, 0.95) 0.81 (0.69, 0.95) 0.79 (0.69, 0.90) PFS, months TIS+CT 6.9 (5.7, 7.2) 5.8 (5.6, 7.3) 7.0 (5.7, 8.4) 6.9 (5.7, 7.3) 6.9 (5.7, 7.2) PBO+CT 6.2 (5.6, 6.9) 5.7 (5.3, 6.9) 6.9 (5.7, 7.1) 6.5 (5.6, 7.0) 6.2 (5.6, 6.9) HR 0.79 (0.68, 0.91) 0.80 (0.64, 0.98) 0.77 (0.64, 0.94) 0.79 (0.67, 0.94) 0.79 (0.69, 0.91) ORR, % TIS+CT 47.3 (42.9, 51.8) 43.6 (37.0, 50.5) 50.2 (44.2, 56.2) 48.0(42.9, 53.1) 47.3 (42.8, 51.8) PBO+CT 40.5 (36.2, 45.0) 32.2 (26.0, 39.0) 46.8 (40.9, 52.8) 43.1(38.1, 48.3) 40.3(36.0, 44.8) ORR difference, % 6.8 (0.6, 12.9) 11.4 (2.3, 20.3) 3.4 (-4.9, 11.6) 4.9 (-2.2, 11.9) 6.9 (0.8, 13.0)
Neoadjuvant epacadostat (INCB024360) combined with short course radiotherapy in patients with locally advanced rectal cancer: Efficacy and safety from a phase 2 trial.
Khushman, M., Park, Haeseong , Huang, K, Parikh, Parag J., Lim, Kian-Huat, Tan, Benjamin, Andreatos, Nikolaos , Mutch, Matthew, Chapman, William, Hunt, Steven, Silviera, Matthew L., Cowan, Michelle L., Wise, Paul E, Kim, Hyun, Ciorba, Matthew A. , Pedersen, Katrina S. , Brown, Amberly , Lim, Kian-Huat, Suresh, Rama , Mutch, Matthew G. , Hunt, Steven R., Mo, Allen , Shetty, Anup S.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2026 | Volume: 44 | Issue: 2_suppl | Pages: 162-162

10.1200/jco.2026.44.2_suppl.162 Get It

162 Background: In preclinical studies, the tryptophan-metabolizing enzyme, Indoleamine 2, 3-dioxygenase 1 (IDO1), promotes resistance to radiation in colorectal cancer, and IDO1 inhibition with epacadostat improves tumor radiosensitivity. In a phase 1 trial, patients (pts) with locally advanced rectal cancer (LARC, n=17) were treated with epacadostat in combination with short course radiotherapy (SCRT) and CAPOX which was well-tolerated, and the recommended phase 2 dose (RP2D) of epacadostat was 400mg BID. Here we report efficacy and safety from the NCI-supported phase 2 (NCT03516708) multicenter, open-label trial (treatment cohort). Methods: Pts were treated with standard of care (SOC) SCRT, then SOC neoadjuvant chemotherapy (NAC) followed by SOC surgical resection or non-operative management (NOM). Epacadostat (400 mg BID) started with SCRT and continued until starting NAC (a minimum of 21 days). Eight pts were enrolled prior to discontinuation of epacadostat by Incyte in February/March 2025. The primary endpoint is Neoadjuvant Rectal (NAR) score. In patients who underwent NOM, we calculated MRI-based tumor regression grade (MR-TRG). Secondary endpoints are pathologic complete response (pCR) rate, complete clinical response (cCR) rate, and progression free survival (PFS). Results: Table 1 summarizes baseline characteristics and endpoints (primary and secondary). NOM was pursued in 7/8 (87.5%) pts, surgical resection was performed on 1/8 (12.5%). At median follow-up of 12 months, local tumor regrowth occurred in 1 pt initially treated with NOM (after tumor regrowth, he underwent salvage surgery and is currently on surveillance). Treatment with epacadostat was interrupted in 2/8 (25%) patients due to grade 3 maculopapular skin rash. Most frequent treatment-emergent adverse events (TEAEs) regardless of causality (all grades (G)/G3-4) were bloating (75%/0%), increased ALT (62.5%/0%), increased AST (50%/0%), nausea (50%/0%), and constipation (50%/0%). Grade 3 diarrhea and grade 3 non-cardiac chest pain occurred in 1 patient each (both unrelated to epacadostat). Conclusions: Epacadostat demonstrates promising efficacy and manageable safety in patients with LARC. The biomarker cohort and correlative studies are ongoing. Clinical trial information: NCT03516708 . Baseline characteristics and endpoints. Patient Age Sex Ethnicity Stage Surgery/NOM NAR MR-TRG cCR/pCR Recurrence 1 52 M Caucasian T3N1 NOM NA 2 Y/NA No 2 45 M Caucasian T3N1 NOM NA 3 Y/NA Local tumor regrowth 3 48 M Caucasian T3N2 NOM NA 3 Y/NA No 4 61 M Caucasian T4N2 NOM NA 3 Y/NA No 5 57 M Caucasian T3N0 NOM NA 1 Y/NA No 6 60 F Caucasian T3N1 Surgery 15 3 N/ypT3N0 No 7 67 M Caucasian T4N0 NOM NA 3 Y/NA No 8 51 M Caucasian T4N2 NOM NA P NA No
P-1941. Risk Factors for Developing Candidemia after Gastrointestinal Perforation and/or Ischemia and Its Outcomes: A Matched Case-Control Study
Barrett, Kemar O. , Stevens, Ryan W W, Strajina, Veljko , Shah, Aditya , Kim, Myeongji , Ranganath, Nischal , Garcia, Sofia Molina , Stevens, Ryan W. , LeMahieu, Allison

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.2109 Get It

Abstract Background Candidemia can occur as a consequence of gastrointestinal (GI) injury. The mortality of candidemia is high, ranging 30-60%, even with treatment with antifungal agents. In this retrospective matched case-control study, we aimed to elucidate the medical and surgical risk factors of developing candidemia in patients who received emergency surgery for GI ischemia and/or perforation, and compare clinical outcomes in these patients with or without candidemia. Methods All patients ≥ 18 years of age who had emergency GI surgery at Mayo Clinic Rochester, MN, for the indication of GI ischemia and/or perforation between 01/01/2018 to 07/31/2024 were included. Cases were defined as patients who developed candidemia during index admission and had no alternative sources of candidemia. Controls and cases were matched 4:1 on age (± 5 years), Charlson Comorbidity Index (± 3), and year of surgery (± 2 years). The relationships between risk factors of interest and case/control were assessed using conditional logistic regression. Results Among medical risk factors, any shock requiring vasopressor (OR = 3.44, 95% CI 1.00, 11.97) or respiratory failure (OR = 8.20, 95% CI 1.04, 64.53) during hospitalization were associated with increased risk of candidemia. Among surgical risk factors, perforation in the upper GI tract was strongly associated with development of candidemia (OR = 16.99, 95% CI 2.11, 136.95) and perforation in the lower GI tract were less likely to lead to candidemia (OR = 0.06, 95% CI 0.01, 0.44). The patients who had diffuse intraabdominal contamination were more likely to develop candidemia compared to those who had no contamination or contained contamination (OR = 3.87, 95% CI 1.33, 11.25). The patients with candidemia showed signal towards higher in-hospital and 30-day mortality, and had significantly longer stay in the hospital. Conclusion Candidemia was more frequently identified in patients with shock, respiratory failure, upper GI perforation, and intra-abdominal contamination, and contributed to significant morbidity and mortality. Further analysis will include building a multivariate logistic regression model to implement prospective trial for early initiation of antifungal therapy for high-risk population. Disclosures All Authors: No reported disclosures
P-4. The Clinical Characteristics and Outcomes of Combination Therapy on Methicillin-susceptible Staphylococcus aureus Bacteremia: A 5-Year Experience
Al-Shokri, Shaikha D., Saleh, Omar M Abu, Yetmar, Zachary, Stevens, Ryan W W, Al-Shokri, Shaikha D. , Kim, Myeongji , Saleh, Omar Abu , Ranganath, Nischal , Yetmar, Zachary A. , Stevens, Ryan W. , Chesdachai, Supavit

Mayo Clinic

Open Forum Infectious Diseases | January 12, 2026 | Volume: 13 | Issue: Supplement_1 | Pages: No page available

10.1093/ofid/ofaf695.235 Get It

Abstract Background Despite effective therapy for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia with anti-staphylococcal penicillins (ASP; e.g., oxacillin, nafcillin) or cefazolin, persistent bacteremia is associated with poorer clinical outcomes and increased complications. Emerging strategies, such as combination therapy with an ASP or cefazolin and ertapenem, have demonstrated the potential to accelerate microbiologic clearance in persistent MSSA bacteremia. However, despite its increasing utilization in clinical practice, data on the effectiveness of this combination regimen remains limited. We sought to describe the clinical characteristics and outcomes of patients with MSSA bacteremia receiving combination therapy. Methods We performed a single-center, retrospective study of adult patients with MSSA bacteremia who received ASP or cefazolin and ertapenem combination therapy from 2019-2023. Time to blood culture clearance, in-hospital mortality, and 90-day relapse were examined. Results A total of 57 patients were included: median age of 65 years [IQR 53-73] with 75.4% male. MSSA bacteremia complicated by infective endocarditis and cardiac implantable electronic device infection occurred in 35.1% and 12.3%, respectively. The median length-of-stay was 16 days [IQR 12-28], and 57.9% required ICU admission. Forty (70.2%) patients underwent source control interventions such as valve replacement, device extraction or surgical debridement. The median duration of bacteremia prior to combination therapy initiation was 4 days [IQR 3-6]. Blood culture clearance occurred in a median of 1 day. The median duration of combination therapy was 4 days [IQR 3-6]. In-hospital mortality was 15.8%. None of the patients surviving the hospitalization experienced relapsed bacteremia within 90 days. Conclusion This study supports growing evidence that combination therapy may offer benefits in managing persistent MSSA bacteremia, specifically with regards to time to blood culture clearance. Further investigation is warranted to determine optimal timing of combination therapy and if known benefits of combination therapy translate into superior clinical outcomes as compared to monotherapy. Disclosures All Authors: No reported disclosures
Immune Checkpoint Inhibitor-Induced Cardiovascular Disease: The Role of Accelerated Senescence in Vascular Dysfunction
Casso-Chapa, Bernardo , Paniagua-Bojorges, Angelica , Palaskas, Nicolas L., Nead, Kevin T. , Samanthapudi, Venkata S.K., Mejia, Gilbert, Kim, Jung Hyun , Deswal, Anita, Herrmann, Joerg, Wang, Guangyu, Kirkland, James L., Krishnan, Sunil, Shen, Ying Hu, Yusuf, Syed Wamique , Iliescu, Cezar, González, Norma Alicia Vazquez, Mendoza, Keila Carolina Ostos , Hanssen, Nordin M.J., Winther, M. De, Yvan-Charvet, L., Nurieva, Roza I., Schadler, Keri , Koutroumpakis, Efstratios, Cooke, J., Le, Nhat-Tu, Abe, Jun-ichi, Kim, Jung Hyun , Palaskas, Nicolas L , Lee, Jonghae , Hoang, O.N. , Lin, Steven H. , Deswal, Anita M , Herrmann, Joerg , Kirkland, James L. , Krishnan, Sunil , Yusuf, Syed Wamique , Jain, Abhishek , Hanssen, Nordin M J , Winther, Menno P.J. de , Yvan-Charvet, Laurent , Nurieva, Roza , Schadler, Keri , Koutroumpakis, Efstratios , Cooke, John P , Kotla, Sivareddy

Mayo Clinic

Antioxidants & Redox Signaling | January 12, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15230864251410546 | PMID 42850906 Get It

Significance: Immune checkpoint inhibitors (ICIs) have transformed cancer therapy by reactivating antitumor immunity and improving outcomes across multiple malignancies. Yet, clinical observations and preclinical studies suggest that ICIs may increase long-term cardiovascular disease risk, including hypertension, atherosclerosis, and thrombosis. The underlying mechanisms remain incompletely defined, highlighting the need for focused investigation into the vascular consequences of immune activation. Recent Advances: ICI-induced immune activation disrupts vascular and immune homeostasis through persistent production of reactive oxygen species (ROS), mitochondrial dysfunction, and accumulation of cell-free DNA (cfDNA). Sustained T-cell activation enhances ROS generation, driving DNA damage and senescence in both endothelial and immune cells. ICIs may also promote endothelial-to-mesenchymal transition (EndoMT) through chronic oxidative and inflammatory signaling, contributing to fibrosis, vascular stiffness, and chronic inflammation. Transforming growth factor-beta, although immunosuppressive in many contexts, can drive profibrotic and EndoMT programs within the vasculature. Other cytokines and regulators, including interleukin-17 and regulator of calcineurin 1, have been implicated in vascular remodeling, atherosclerosis, and hypertension. Critical Issues: The relative roles of ROS, mitochondrial dysfunction, cfDNA-driven inflammation, and EndoMT in ICI-associated vascular senescence remain unclear. While inflammation-induced vascular damage is well-recognized, direct ICI-specific mechanisms require stronger evidence. How senescent endothelial and immune cells influence therapy resistance and remodeling of the tumor microenvironment also remains to be defined. Future Directions: Mitochondrial and cytosolic ROS sources—arising from electron leakage during oxidative phosphorylation and NADPH oxidases activity—shape immune signaling and sustain T-cell activation during checkpoint blockade. The DNA damage response kinases ataxia-telangiectasia mutated and ATM- and Rad3-related, activated by oxidative and replicative stress, engage p53-dependent senescence pathways in endothelial and immune cells. Future studies should evaluate biomarkers such as cfDNA and thrombospondin-1 and explore senescence-targeting or redox-modulating interventions that may alleviate cardiovascular toxicity without diminishing antitumor efficacy. This review outlines mechanistic pathways linking ICIs to vascular dysfunction and senescence, integrating preclinical data with emerging clinical insights. It distinguishes established processes from ICI-specific hypotheses and identifies key gaps requiring clinical validation. Antioxid. Redox Signal. 00, 000–000.
COMPREHENSIVE GENETIC INVESTIGATION REVEALS HETEROGENEOUS PATHWAYS TO OBSTRUCTIVE SLEEP APNEA
Justice, Anne E. , Pahl, Matthew C. , Gupta, Shreyash , Kim, Soriul , Thorleifsson, Gudmar, Gutierrez, Alejandro , Oliveira, Fernando Andrade de , Ackert‐Bicknell, Cheryl L. , Benediktsdottir, Bryndis, Boero, Jaime, Borthwick, Kenneth M., Chen, N., Cistulli, Peter A. , Favazzo, Lacey J. , Gottlieb, Daniel J. , Hakonarson, H., Kirchner, H. Lester , Mazzotti, Diego R, Mentch, Frank , Morgentheler, Timothy I, Penzel, Thomas, Pippin, James A. , Rasmussen-Torvik, Laura J, Shin, Chol, Singh, Bhajan, Sofer, T., Villani, David A. , Wells, Andrew D, Zee, Phyllis, Jonsdottir, Ingileif, Gislason, Thorarinn, Robishaw, Janet, Stefansson, K., Grant, Struan FA., Pack, A., Þorleifsson, Guðmar , Kim, Soriul , Thorleifsson, Gudmar , Manduchi, Elisabetta , Gutierrez, Alejandro , Cistulli, Peter A , Gottlieb, Daniel J , Magalang, Ulysses J , Mazzotti, Diego R , Mentch, Frank D , Morgenthaler, Timothy I , Rasmussen-Torvik, Laura J , Shin, Chol , Singh, Bhajan , Sofer, Tamar , Williams, Marc S , Zuscik, Michael J , Jonsdottir, Ingileif , Gislason, Thorarinn , Stefánsson, Kári , Keenan, Brendan T , Chittoor, Geetha , Hoskens, Hanne , Josyula, Navya Shilpa , Oliveira, Fernando Andrade, Malow, Beth A. , McArdle, Nigel , Morgenthaler, Timothy I. , Penzel, Thomas , Sofer, Tamar , Veatch, Olivia J. , Robishaw, Janet D. , Stefánsson, Kāri , Grant, Struan F.A. , Hallgrímsson, Benedikt , Pack, Allan I

Mayo Clinic

No container title available | January 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.01.08.26343696 | PMID 41542692 Get It

ABSTRACT Obstructive sleep apnea (OSA) is a common, heritable disorder with diverse clinical presentations and etiologies. We conducted a genome-wide association meta-analysis of 492,107 individuals, including 46,028 OSA cases, identifying 14 genome-wide significant loci, eight of which are novel. Analyses adjusting for body mass index (BMI) revealed three loci independent of obesity, implicating alternative biological pathways contributing to disease. Integrative functional analyses, including chromatin interaction mapping, fine-mapping, and eQTL colocalization, prioritized candidate effector genes. Notably, implicated genes in chondrocytes were associated with craniofacial morphology in both mouse and human multivariate genotype-phenotype mapping, supporting a role for craniofacial structure in OSA risk. These findings highlight key genetic pathways (obesity-related, neurological, and craniofacial) underlying the development of OSA, offering new insights into its complex etiology.
Impact of Age and Sex on Extra‐Brain, Off‐Target Binding in Tau PET Scans (18F‐FTP)
Ghatamaneni, Sujala, Kim, Daneil, Nycklemoe, Marin, Choi, Yurim Claire , Apgar, Christopher, Kandimalla, Mahathi , Jacobson, David N, Kung, Tiffany, Sharma, Vamika, Hol, Haakon R. , Albertson, Sabrina M., Schwarz, Christopher G, Gunter, Jeffrey L. , Petersen, Ronald, Jack, Clifford R., Lowe, VJ, Ghatamaneni, Sujala, Apgar, Christopher J., Kung, Tiffany, Lim, Seokbeen , Lundt, Emily S. , Schwarz, Christopher G. , Petersen, Ronald, Jack, Clifford R. , Min, Hoon-Ki Paul

Mayo Clinic

Alzheimer's & Dementia | January 11, 2026 | Volume: 21 | Issue: S2 | Pages: No page available

10.1002/alz70856_107719 Get It

Abstract Background The tau PET imaging with 18F‐flortacipir (18F‐FTP) has focused interest in accurately tracking longitudinal tau changes in Alzheimer's disease [1]. Thus, minimizing variability is critical. Off‐target signal has the potential to complicate interpretation of tau‐PET imaging due to potential spillover or bleed‐in effects, with increased effects seen in later stages of Alzheimer's due to cerebral atrophy and proximity of off‐target areas to relevant cortical areas[2]. Previously, we demonstrated the effect of uptake period activity on 18F‐FTP signal. With increasing recent interest in demographic factors that may affect off‐target binding, we investigated the effect of age in extra‐cerebral off‐target signal in 18F‐FTP PET imaging. Method Standard 18F‐FTP PET protocol was performed in 330 participants. Two independent readers measured tau uptake in predetermined off‐target regions, including extraocular muscle, meninges, and occipital bone among others. Linear regression models assessed the relationship between participants’ age, sex, and tau uptake values (SUV and SUVr) (SUV = (Tissue radioactivity concentration / Injected dose) / Body weight & SUVr = SUV of target region/ SUV of reference region.) Result Sex had a significant effect on off‐target signal in most brain regions, with variable positive or negative correlation based on area. Notably, SUV in the eyeball‐retina, occipital bone, upper skull meninges all showed significant positive correlation with sex, with ‘male’ status generally associated with lower SUV. The greatest effect of sex was observed in superior skull meninges, occipital bone, and internal carotid artery ( p <0.001). Age showed minimally affected SUV and SUVr in off‐target regions. SUVr values show a significant correlation with SUV values of upper skull meninges in sex. Cognitive status did not significantly affect off‐target SUV. Conclusion We observed that sex significantly affected extra‐brain off‐target signal in 18F‐FTP PET imaging, while age has minimal effect, adding to previous evidence of off‐target binding within brain regions. Further evaluation is necessary to understand the age‐related effects on off‐target regions. As a result, the variability introduced by sex may pose challenges to studying tau accumulation.